Table 2.
Failure frequency by API/API combination in prevalence survey
| API/API combination | No of publications | No of data points | Failure frequency % (n/N) |
| Ritonavir | 1 | 2 | 100.0 (2/2) |
| Indinavir | 4 | 6 | 42.9 (6/14) |
| Lopinavir-ritonavir | 4 | 5 | 18.2 (8/44) |
| Lamivudine-zidovudine-nevirapine | 3 | 3 | 8.2 (7/85) |
| Stavudine | 6 | 13 | 4.2 (4/96) |
| Efavirenz | 10 | 23 | 3.6 (7/193) |
| Lamivudine-nevirapine-stavudine | 7 | 14 | 2.8 (5/177) |
| Nevirapine | 12 | 24 | 2.6 (5/192) |
| Zidovudine | 7 | 18 | 1.9 (2/103) |
| Lamivudine | 6 | 18 | 1.5 (2/132) |
| Lamivudine-zidovudine | 5 | 11 | 1.5 (2/134) |
| Antiretroviral-unspecified | 2 | 2 | 0.0 (1/2,325) |
| Abacavir | 3 | 3 | 0.0 (0/33) |
| Abacavir-lamivudine | 1 | 1 | 0.0 (0/1) |
| Amprenavir | 1 | 1 | 0.0 (0/1) |
| Didanosin | 4 | 4 | 0.0 (0/20) |
| Efavirenz-lamivudine-tenofovir disiproxil | 1 | 1 | 0.0 (0/29) |
| Emtricitabine-efavirenz-tenofovir disiproxil | 2 | 2 | 0.0 (0/28) |
| Emtricitabine-tenofovir disoproxil | 2 | 4 | 0.0 (0/30) |
| Lamivudine-stavudine | 4 | 5 | 0.0 (0/43) |
| Saquinavir | 1 | 2 | 0.0 (0/2) |
| Tenofovir disoproxil | 3 | 5 | 0.0 (0/25) |
| Tenofovir disoproxil-lamivudine | 1 | 1 | 0.0 (0/3) |
| Total | 19 | 168 | 1.4 (51/3713) |
Because of the limited number of samples tested for quality in the studies included in this review, the figures should not be interpreted as representative of the prevalence of specific SF antiretroviral medicines (please refer to the discussion section of the current paper for more details).
API, active pharmaceutical ingredient; SF, substandard and falsified.